Search results
FDA Advisers Like Lilly’s Alzheimer’s Drug. It’s Good News for Biogen.
Barrons.com· 5 days agoThat is likely good news for Biogen and Eisai whose similar Alzheimer’s therapy will benefit from a...
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Augtyro
Zacks via Yahoo Finance· 2 days agoThe FDA approves Bristol Myers' (BMY) cancer drug Augtyro for the treatment of adult and pediatric...
FDA panel approves Alzheimer's drug that can slow disease
KSDK St. Louis· 6 days ago“I thought the evidence was very strong in the trial showing the effectiveness of the drug,” said...
FDA warns some oysters, clams could be contaminated with paralytic shellfish toxins
FOX 7 Austin· 2 days agoA warning was issued by the Food and Drug Administration (FDA) about some oysters and clams that may...
FDA panel backs Eli Lilly’s Alzheimer’s drug
The Hill via Yahoo News· 6 days agoA federal advisory panel on Monday voted in favor of recommending Eli Lilly’s new drug that is under consideration for its potential to slow the...
FDA panel approves Alzheimer's drug that can slow disease
WUSA 9 Washington, D.C.· 6 days ago“I thought the evidence was very strong in the trial showing the effectiveness of the drug,” said...
FDA took months to react to complaint about Abbott infant formula factory, audit finds
The News-Times· 3 days agoThe Department of Labor received the email and three days later forwarded it to an FDA address...
FDA grants IND clearance for Allay’s trial of post-surgical pain treatment
Clinical Trials Arena via Yahoo Finance· 4 days agoThe US Food and Drug Administration (FDA) has granted clearance to Allay Therapeutics’...
FDA: Recalled Florida cucumbers with salmonella might not be linked to outbreaks after all
Daytona Beach News-Journal via Yahoo News· 4 days agoBut possibly not the cucumbers recalled by a Florida distributor in Delray, as previously suspected....
FDA official: The risk of secondary cancer from CAR-T therapy, pioneered at Penn, is less than...
Philly.com· 2 days agoThe risk of secondary cancer after CAR-T therapy, pioneered at Penn, is less than regulators feared...